Nomura Holdings Inc. Acquires 133,801 Shares of Johnson & Johnson (NYSE:JNJ)

Share on StockTwits

Nomura Holdings Inc. raised its holdings in Johnson & Johnson (NYSE:JNJ) by 114.9% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 250,245 shares of the company’s stock after buying an additional 133,801 shares during the period. Nomura Holdings Inc.’s holdings in Johnson & Johnson were worth $34,592,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Billeaud Capital Management Inc. grew its position in Johnson & Johnson by 0.4% in the 2nd quarter. Billeaud Capital Management Inc. now owns 44,014 shares of the company’s stock valued at $6,130,000 after acquiring an additional 169 shares during the last quarter. Meeder Asset Management Inc. lifted its holdings in shares of Johnson & Johnson by 11.1% in the 2nd quarter. Meeder Asset Management Inc. now owns 109,690 shares of the company’s stock worth $15,277,000 after buying an additional 10,927 shares during the period. Archford Capital Strategies LLC lifted its holdings in shares of Johnson & Johnson by 11.2% in the 2nd quarter. Archford Capital Strategies LLC now owns 21,997 shares of the company’s stock worth $3,064,000 after buying an additional 2,211 shares during the period. Marino Stram & Associates LLC lifted its holdings in shares of Johnson & Johnson by 1.2% in the 2nd quarter. Marino Stram & Associates LLC now owns 32,199 shares of the company’s stock worth $4,485,000 after buying an additional 380 shares during the period. Finally, Palisades Hudson Asset Management L.P. lifted its holdings in shares of Johnson & Johnson by 42.6% in the 2nd quarter. Palisades Hudson Asset Management L.P. now owns 2,241 shares of the company’s stock worth $312,000 after buying an additional 669 shares during the period. 72.01% of the stock is currently owned by institutional investors.

Shares of NYSE JNJ traded up $1.27 during mid-day trading on Friday, reaching $131.38. 359,115 shares of the company were exchanged, compared to its average volume of 7,392,434. The company has a quick ratio of 1.04, a current ratio of 1.33 and a debt-to-equity ratio of 0.46. The stock has a market cap of $342.22 billion, a price-to-earnings ratio of 16.06, a P/E/G ratio of 2.19 and a beta of 0.68. Johnson & Johnson has a 1 year low of $121.00 and a 1 year high of $148.99. The firm has a 50-day moving average of $130.02 and a 200 day moving average of $135.75.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, July 16th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.42 by $0.16. The firm had revenue of $20.56 billion during the quarter, compared to analysts’ expectations of $20.39 billion. Johnson & Johnson had a return on equity of 38.63% and a net margin of 20.08%. The firm’s quarterly revenue was down 1.3% on a year-over-year basis. During the same period in the prior year, the business posted $2.10 EPS. On average, equities analysts forecast that Johnson & Johnson will post 8.6 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were paid a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.89%. The ex-dividend date was Monday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 46.45%.

JNJ has been the subject of several research reports. Barclays initiated coverage on Johnson & Johnson in a report on Friday, June 21st. They issued a “hold” rating and a $140.00 target price for the company. Zacks Investment Research cut Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 target price for the company. in a report on Thursday, July 18th. Royal Bank of Canada reiterated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, July 16th. Morgan Stanley reiterated an “equal weight” rating and issued a $145.00 target price on shares of Johnson & Johnson in a report on Tuesday, August 27th. Finally, Goldman Sachs Group set a $169.00 target price on Johnson & Johnson and gave the stock a “buy” rating in a report on Tuesday, August 27th. Five investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $150.60.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: What are momentum indicators and what do they show?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.